slide 2 / 27 · slide 9 / 27 slide 10 / 27 page 5. undefined s5-02 neratinib after...
TRANSCRIPT
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 1 / 27
Slide 2 / 27
Page 1
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 3 / 27
Slide 4 / 27
Page 2
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 5 / 27
Slide 6 / 27
Page 3
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 7 / 27
Slide 8 / 27
Page 4
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 9 / 27
Slide 10 / 27
Page 5
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 11 / 27
Slide 12 / 27
Page 6
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 13 / 27
Slide 14 / 27
Page 7
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 15 / 27
Slide 16 / 27
Page 8
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 17 / 27
Slide 18 / 27
Page 9
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 19 / 27
Slide 20 / 27
Page 10
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 21 / 27
Slide 22 / 27
Page 11
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 23 / 27
Slide 24 / 27
Page 12
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 25 / 27
Slide 26 / 27
Page 13
undefined
S5-02 NERATINIB AFTER TRASTUZUMAB-BASED ADJUVANT THERAPY IN EARLY-STAGE HER2+ BREAST CANCER: 3-YEAR ANALYSIS FROM A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL (EXTENET)Speaker: Arlene Chan
Slide 27 / 27
Page 14